Johnson & Johnson (JNJ) Intangibles (2009 - 2026)

Johnson & Johnson's (JNJ) quarterly Intangibles came in at $49.1 billion in Q1 2026, up 33.48% year-on-year from $36.8 billion in Q1 2025, and down 2.66% quarter-over-quarter from $50.4 billion in Q4 2025.

Johnson & Johnson (JNJ) Intangibles (2009 - 2026) Analysis & Trends

Johnson & Johnson has disclosed Intangibles across 18 years of filings, most recently posting $49.1 billion for Q1 2026.

  • Intangibles for Q1 2026 came in at $49.1 billion, up 33.48% year-over-year; the trailing twelve-month figure through Mar 2026 was $49.1 billion (up 33.48% YoY), and the FY2025 annual result was $50.4 billion, up 33.99% from the prior year.
  • Intangibles came in at $49.1 billion for Q1 2026 at Johnson & Johnson, down from $50.4 billion in the prior quarter.
  • In the past five years, Intangibles ranged from a high of $50.4 billion in Q4 2025 to a low of $34.2 billion in Q4 2023.
  • The 5-year median for Intangibles is $41.4 billion (2022), against an average of $42.3 billion.
  • Across the five-year window, Intangibles decreased 27.74% in 2024 and soared 33.99% in 2025, its largest moves.
  • Johnson & Johnson's Intangibles stood at $40.3 billion in 2022, then dropped by 15.27% to $34.2 billion in 2023, then rose by 10.07% to $37.6 billion in 2024, then jumped by 33.99% to $50.4 billion in 2025, then retreated by 2.66% to $49.1 billion in 2026.
  • The last three Intangibles figures came in at $49.1 billion (Q1 2026), $50.4 billion (Q4 2025), and $48.7 billion (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Intangibles (Qtr)
1 Gsk 93,699,046.73 Bn 93,699,041.77 Bn 7.76 Bn 24.45 Bn
2 Eli Lilly 1,012.06 Bn 1,006.77 Bn 16.22 Bn 7.37 Bn
3 Johnson & Johnson 560.67 Bn 538.62 Bn 15.96 Bn 49.06 Bn
4 AbbVie 402.20 Bn 392.85 Bn 10.78 Bn 50.87 Bn
5 Merck 298.59 Bn 292.94 Bn 12.09 Bn 25.75 Bn
6 Amgen 188.77 Bn 176.74 Bn 5.87 Bn 21.38 Bn
7 Gilead Sciences 160.22 Bn 152.49 Bn 5.52 Bn 16.38 Bn
8 Pfizer 148.19 Bn 135.42 Bn -1.21 Bn 52.56 Bn
9 Bristol Myers Squibb 116.72 Bn 106.26 Bn 8.07 Bn 18.24 Bn
10 Novartis Ag 109.78 Bn 109.09 Bn - 10.60 Bn

Historic Data

Download Data
DateValue
Mar 29, 2026 49.06 Bn
Dec 28, 2025 50.40 Bn
Sep 28, 2025 48.74 Bn
Jun 29, 2025 49.84 Bn
Mar 30, 2025 36.76 Bn
Dec 29, 2024 37.62 Bn
Sep 29, 2024 39.49 Bn
Jun 30, 2024 39.73 Bn
Mar 31, 2024 34.29 Bn
Dec 31, 2023 34.18 Bn
Oct 1, 2023 35.02 Bn
Jul 2, 2023 46.25 Bn
Apr 2, 2023 47.45 Bn
Jan 1, 2023 38.49 Bn
Oct 2, 2022 40.34 Bn
Jul 3, 2022 42.41 Bn
Apr 3, 2022 44.42 Bn
Jan 2, 2022 46.39 Bn
Oct 3, 2021 47.78 Bn
Jul 4, 2021 50.24 Bn